Proven track record leading departments and project teams to successfully advance molecules to clinical trials, with a reputation for building productive and collegial teams. Experienced and accomplished research experience in multiple disease areas (oncology, pain, antibacterials, diabetes, IBD, osteoporosis), and target types (kinase, GPCR, ion channel, phosphatase, protease). Member of early and late stage clinical development teams (IND -> NDA -> commercialization). Motivated and goal-oriented scientist adept at working both in biotech and large pharma environments. Experience co-leading entire Chemistry Dept., with > 40 FTEs. Responsible for leading external collaborations with academia and small biotech. Proven leader in enhancing project team execution, crisp decision making, introducing innovative technologies, structure based drug design (SBDD), outsourcing, and developing junior staff as scientists and managers.

Vice President, Chemistry @ • Head of chemistry for Morphic Rock Therapeutic, a Polaris Partners company, founded by Prof. Tim Springer (Boston Children's Hospital/ Harvard) • Responsible for creating the chemistry department, initiating multiple integrin projects, and working closely with key collaborators (Schrödinger, ChemPartner) From June 2015 to Present (7 months) Senior Director of Medicinal Chemistry @ • Co-leader of Cubist Medicinal Chemistry Department • Portfolio leader for multiple acute care projects • Led the advancement of development candidates to the clinic • Interim co-leader of entire Discovery Chemistry group (medicinal chemistry, outsourcing, computational chemistry, chemoinformatics, sample bank): 2013-2014 • Responsible for department budget decisions and tracking • Led effort to reorganize project teams across Cubist Research for greater efficiency, impact, empowerment and accountability • Responsible for managing talent: hiring, employee development and workforce planning • Assisted with multiple successful grant applications • Participated on Ceftolozane/ Tazobactam development core team during advanced clinical trials, NDA submission, and market positioning From December 2011 to May 2015 (3 years 6 months) Director @ • Led a group of 12 chemists directly (4 Ph.D., 8 B.S./M.S.) • Project team leader for multiple projects in the pain and antibacterial space, capable of leading 3 large projects simultaneously (> 50 internal FTEs) • Recognized with Cubist Employee of the Year Award, and Cubist Team of the Year Award as team leader (both corporate-wide) • Key leader of external collaborations, including Heptares (GPCR structural biology) and Hydra (ion channels) • Managed outsourced resources on multiple projects • Participated on an early clinical development team advancing a novel pain therapy; helped set translational biomarker and clinical strategy through CTA/ IND From April 2008 to November 2011 (3 years 8 months) Senior Principal Scientist @ • Lead medicinal chemistry designer in the metabolic disease therapeutic area • Advanced projects for diabetes, frailty and osteoporosis • Closely integrated with technology groups to advance chemoinformatics and computational chemistry • Simultaneously led exploratory chemistry efforts on several projects through outsourcing From January 2006 to March 2008 (2 years 3 months) Principal Scientist @ • Project team leader of an oncology project with > 20 FTEs (chemistry, biology, computational chemistry, PK, toxicology, and pharm. sci.). Discovered the crucial molecular design that led to high kinase selectivity and efficacy. Successively achieved a development candidate for human clinical trials • Utilized both high speed analoging and traditional organic synthesis in the pursuit of novel drugs • Analyzed HTS campaigns and advanced novel leads • Conceived and advanced an idea for a novel exploratory project targeting tumor stem cells. Successfully advocated for project launch and led initial team. Compound currently in phase 2 human clinical trials From January 2002 to December 2005 (4 years) Senior Scientist @ • Advanced multiple oncology projects to treat incurable cancers • Initiated a global kinase selectivity panel. Coordinated requests and data with analysis leading to a Pfizer Recognition Award • Successfully directed up to 3 off-shore and U.S. outsourced chemists • Became proficient in patent analysis and publication From December 1999 to December 2001 (2 years 1 month)

Ph.D., Organic chemistry @ Stanford University From 1995 to 1999 B.S., Chemistry and Cellular Molecular Biology @ University of Michigan From 1991 to 1995 Blaise Lippa is skilled in: Medicinal Chemistry, Drug Design, Drug Discovery, Lead Change, Organic Chemistry, Drug Development, Cheminformatics, ADME, Project Leadership, Portfolio Management, High Throughput Screening, Life Sciences